Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06541509 · ClinicalTrials.gov registry record · Phase 1
Mechanisms of Semaglutide Therapy in Heart Failure Patients
A Phase 1 study of Obesity and Heart Failure, sponsored by University Medical Centre Ljubljana.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT06541509 is a Phase 1 study of Obesity and Heart Failure that is actively recruiting participants, run by University Medical Centre Ljubljana. The registered enrollment target is 10 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT06541509, a Phase 1 study of Obesity and Heart Failure, is actively recruiting participants, sponsored by University Medical Centre Ljubljana.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion. In addition, GLP-1 receptor agonists appear to have multiple extrapancreatic actions, which remain poorly defined. In large clinical trials, semaglutide improved the outcomes in obese patients, patients with heart failure with preserved ejection fraction, and decreased the heart failure hospitalizations in patients with type 2 diabetes. The aim of the present study is to investigate the underlying mechanisms of the beneficial clinical effects of semaglutide in the setting of chronic heart failure.
Conditions Studied
Interventions
- DRUG Semaglutide
Study Locations (3)
California
- Greenstone Biosciences - Palo Alto
- Stanford Cardiovascular Institute - Stanford
Other
- University Medical Center Ljubljana - Ljubljana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2025-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06541509
The ClinicalTrials.gov registry entry for NCT06541509 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (99% lower). The listed sponsor is University Medical Centre Ljubljana, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 1 intervention - of which Semaglutide is the first listed.
NCT06541509 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Other.
Frequently Asked Questions
What is clinical trial NCT06541509 about?
NCT06541509 is a clinical study titled "Mechanisms of Semaglutide Therapy in Heart Failure Patients". Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, primarily used for treatment of type-2 diabetes mellitus. GLP-1 receptors are present on pancreatic islet β-cells, δ-cells and α-cells. Their stimulation increases insulin and somatostatin secretion, and decreases glucagon secretion....
What is the current status of trial NCT06541509?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2024-07-10. Estimated completion is 2025-09-01.
What conditions does trial NCT06541509 study?
This clinical trial studies the following conditions: Obesity, Heart Failure.
What interventions are being tested in trial NCT06541509?
The interventions under investigation include: Semaglutide (DRUG).
Who is sponsoring clinical trial NCT06541509?
This trial is sponsored by University Medical Centre Ljubljana, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06541509 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Hip Flexion Feedback System for Exercise Monitoring in Individuals With Osteoarthritis and Obesity
RECRUITING · Phase 1
-
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
RECRUITING · Phase 1
-
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
RECRUITING · Phase 1
-
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
RECRUITING · Phase 1
-
A Study of LY3971297 in Healthy Participants
RECRUITING · Phase 1
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.